HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor
Open Access
- 1 July 1998
- journal article
- Published by Elsevier in The Lancet
- Vol. 352 (9123), 199-200
- https://doi.org/10.1016/s0140-6736(98)24029-3
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral TherapyScience, 1997
- Combination of a Drug Targeting the Cell with a Drug Targeting the Virus Controls Human Immunodeficiency Virus Type 1 ResistanceAIDS Research and Human Retroviruses, 1997
- Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamideThe Lancet, 1997
- Hydroxyurea as an Inhibitor of Human Immunodeficiency Virus-Type 1 ReplicationScience, 1994
- Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine.The Journal of Experimental Medicine, 1989